Table 3.
Proportional cox hazard regression analysis of predictors associated with recurrence among adult breast cancer patients at Black Lion Specialized Hospital, Addis Ababa Ethiopia, 2018
| Variable | Recurrence | CHR | AHR | |
|---|---|---|---|---|
| Yes | No | |||
| Place of origin | ||||
| Addis Ababa | 60 | 268 | 1 | 1 |
| Non-Addis Ababa | 35 | 150 | 1.04 (1.00-2.45)* | 1.50 (0.80-3.13) |
| Menopause status | ||||
| Premenopausal | 59 | 304 | 1 | 1 |
| Postmenopausal | 36 | 126 | 1.50 (0.65-3.65) | 1.80 (0.72-6.13) |
| Body mass index (kg/m2) | ||||
| 18.5-24.9 | 49 | 297 | 1 | 1 |
| 25.0-29.9 | 37 | 110 | 2.03 (0.91-5.08) | 1.20 (0.76-6.89) |
| ≥ 30.0 | 9 | 11 | 4.90 (0.71-7.92) | 2.80 (0.47-4.66) |
| Comorbidity | ||||
| Yes | 62 | 110 | 5.30 (1.13-10.40)* | 1.50 (0.73-4.29) |
| No | 33 | 310 | 1 | 1 |
| Stage of breast cancer | ||||
| I | 4 | 24 | 1 | 1 |
| II | 27 | 140 | 1.16 (1.00-3.08)* | 1.30 (0.64-2.08) |
| III | 64 | 254 | 1.51 (1.30-5.92)* | 2.50 (1.26-9.42)* |
| Histology grade | ||||
| Grade I | 10 | 63 | 1 | 1 |
| Grade II | 43 | 203 | 1.34 (1.40-6.09)* | 1.73 (0.67-4.53) |
| Grade III | 42 | 152 | 1.74 (1.28-14.06)* | 2.80 (1.14-10.31)* |
| Deep surgical margin | ||||
| Free | 30 | 317 | 1 | 1 |
| Involved | 65 | 101 | 6.80 (1.25-12.17)* | 3.60 (2.14-8.61)* |
| No. of involved lymph node | ||||
| < 2 | 33 | 90 | 1 | 1 |
| ≥ 2 | 62 | 178 | 0.94 (0.81-4.42) | 0.60 (0.53-3.20) |
| Tumor size (cm) | ||||
| ≤ 2.5 | 11 | 102 | 1 | 1 |
| 2.5-5.0 | 31 | 146 | 1.96 (1.19-6.02)* | 1.60 (0.73-5.832) |
| > 5.0 | 53 | 170 | 2.89 (1.17-5.71)* | 1.50 (0.891-4.123) |
| Hormone therapy | ||||
| No | 49 | 143 | 1 | 1 |
| Yes | 46 | 275 | 0.48 (0.28-0.52)* | 0.63 (0.21-0.89)* |
| Lymph node status | ||||
| Negative | 36 | 327 | 1 | 1 |
| Positive | 59 | 91 | 5.88 (3.39-13.24)* | 2.60 (1.14-10.31)* |
| Type of surgery | ||||
| MRM | 72 | 375 | 1 | 1 |
| BCS | 24 | 42 | 2.97 (0.87-5.98) | 1.43 (0.48-4.62) |
| Adjuvant chemotherapy | ||||
| Yes | 55 | 341 | 0.31 (0.21-0.90)* | 0.87 (0.64-4.81) |
| No | 40 | 77 | 1 | 1 |
| Estrogen receptor | ||||
| Negative | 57 | 165 | 2.12 (1.36-6.27)* | 1.80 (1.53-7.62)* |
| Positive | 38 | 233 | 1 | 1 |
Values are presented as number only or hazard ratio (95% CI). Covariates adjusted in the final model: stage, histological grade, lymph node status, deep surgical margin, hormone therapy, adjuvant chemotherapy, tumor size, and estrogen receptor. CHR, crude hazard ratio AHR, adjusted hazard ratio. *The asterisks indicatethat the variables significantly associated with the outcome at bivariable and multivariable analysis with 95% level of significant (P < 0.05).